Saturday 17 October 2026
Export INTS’s income statement to Excel — free account
Intensity Therapeutics Inc.
INTS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 65.9%, free cash flow grew 4.72% and total debt fell 34.7%, each against the same quarter a year earlier.
3.35
0.03
−0.89%
Follow INTS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.00 | 4.86 | 5.92 | 3.60 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.08 | 4.04 | 3.78 | 2.56 | |
Debt/Assets |
0.54% | 0.57% | 0.56% | 0.91% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.75 | 0.79 | 0.89 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.86) | (0.72) | (1.77) | (1.39) | |
Cash per Share |
3.52 | 4.04 | 8.79 | 4.10 | |
Shareholders Equity per Share |
3.40 | 3.94 | 8.76 | 4.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.40 | 3.94 | 8.76 | 4.19 | |
Free Cash Flow |
(2.34) | (1.83) | (2.40) | (2.39) | |
Working Capital |
8.98 | 8.66 | 10.56 | 5.91 | |
Net Current Asset Value |
8.92 | 8.59 | 10.48 | 5.82 | |
| Other line items | |||||
Quick Ratio |
4.24 | 4.57 | 5.56 | 3.11 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.86) | (0.72) | (1.77) | (1.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.10 | 1.11 | 0.90 | 1.11 | |
Average Assets |
7.98 | 7.68 | 9.44 | 7.40 | |
Average Common Equity |
5.70 | 5.16 | 7.40 | 5.00 |
Columns are period end dates